GAD2 and type 1 diabetes mellitus: This clinical program was possible thanks to the cost-effective production of large amounts of insulin in recombinant microbes (Baeshen et al., 2014) and the dramatic results obtained in a subset of patients paves the way toward future immunomodulatory strategies using other T1D autoantigens such as GAD65.